Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-24-119012
Filing Date
2024-11-14
Accepted
2024-11-14 16:30:23
Documents
1
Group Members
ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLCATLAS VENTURE ASSOCIATES XI, L.P.ATLAS VENTURE ASSOCIATES XI, LLCATLAS VENTURE OPPORTUNITY FUND I, L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13G/A tm2428252d3_sc13ga.htm SC 13G/A 101418
  Complete submission text file 0001104659-24-119012.txt   103255
Mailing Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Atlas Venture Fund XI, L.P. (Filed by) CIK: 0001708269 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 828 WINTER STREET WALTHAM MA 02451
Business Address 828 WINTER STREET WALTHAM MA 02451 617-833-1027
Xilio Therapeutics, Inc. (Subject) CIK: 0001840233 (see all company filings)

EIN.: 851623397 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-92962 | Film No.: 241463107
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)